Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > BUSINESS
BUSINESS
- Tolvaptan Suppresses Rate of Increase in Total Kidney Volume by 50%: Otsuka
November 7, 2012
- Eli Lilly Japan, Chugai to Terminate Comarketing Agreement for Evista
November 7, 2012
- Takeda to Buy Envoy of US to Reinforce Drug Discovery Prowess
November 7, 2012
- Ono Achieves Target Reduction of Sales Ratio of Long-Listed Drugs to Mid-50% Level: President Sagara
November 7, 2012
- Generic Sales Ratio Exceeds 80% for First Time in Interim Results: Nippon Chemiphar
November 6, 2012
- Abbott Splits into Two Companies; Research-Based Pharmaceuticals, Diversified Medical Products
November 6, 2012
- Abbott Japan Spins Off New Drug Biz, Establishes New Firm “AbbVie”
November 6, 2012
- Sawai’s Status Improved Within Mediceo by Utilizing ARs
November 6, 2012
- Asahi Kasei Pharma 1st Half Sales Show Significant Growth, Teribone May Exceed Peak Sales in 1st Year
November 6, 2012
- Astellas Logs Sales of 25.5 Bil. Yen in Oncology Sector, Investments Bearing Fruit: Pres. Hatanaka
November 5, 2012
- Shionogi Enjoys Sales, Profit Growth in 1st Half, 8 Strategic Products Make Up 50% of Japan Sales
November 5, 2012
- Domestic Drug Makers’ Major Products See Sharp Declines in 1st Half; Sales of Aricept, Lipitor Down 30%
November 5, 2012
- Eisai to Go on Offensive for Aricept by Introducing Consultation Date Reminder Service for Patients: President Naito
November 5, 2012
- Astellas Discontinues Development of SGLT-2 Inhibitor Ipragliflozin in Europe, US; Development in Japan to Go Forward
November 5, 2012
- Astellas: Slight Sales Decline in 1st Half due to Strong Yen, Domestic Sales Virtually Unchanged
November 5, 2012
- “Lecture Meeting Fever” as Companies Seek New Ways to Interact with Doctors Under Tougher Restrictions on Settai
November 5, 2012
- Medipal HD Reports Sharp Increase in Operating Profits in First Half
November 2, 2012
- Eisai Suffers Double-Digit Sales, Profit Falls in 1st Half as Mainstay Drugs Slump
November 2, 2012
- Sales Target for Prasugrel Achievable Despite Add’l Indication Dropped: Daiichi Sankyo Pres. Nakayama
November 2, 2012
- Shionogi Licenses Alzheimer’s Disease Treatment to Janssen Pharmaceuticals of US
November 2, 2012
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…